Archive for the ‘ COPD ’ Category

I was provided this link from Eric Chung, Respiratory Therapy Professional Practise Lead at Eagle Ridge Hospital which easily illustrates the available services in BC for Pulmonary Rehab and Lung Education.

The map is interactice and provides addresses and contact information.

 

Thanks Eric!

 

Excellent education link

This educational series on combination therapy for asthma and COPD examines recent evidence and strategies for combining bronchodilators and inhaled corticosteroids in the management of asthma or COPD. The expert faculty will assess clinical data and provide insights on how they may translate to clinical practice in Canada.

Access site HERE

astraeducation

printer_logo_RS

In patients with chronic obstructive pulmonary disorder (COPD), inflammatory changes impact their ability to breathe properly. Patients will eventually retain carbon dioxide (CO2) as their efforts to maintain normal CO2levels proves difficult. Experts have long debated whether chronically elevated carbon dioxide levels affect how a patient handles oxygen. As a result, a theory developed that administering oxygen obliterated the drive to breathe.

The problem with the Hypoxic Drive Theory is that it’s a myth concocted on incomplete evidence and often elicits a controversial response, according to John Bottrell, RT, Spectrum Health Ludington Hospital, and COPD/asthma expert for healthcentral.com.

For hypoxemic patients with COPD, most medical experts now recommend administering the lowest amount of oxygen needed to maintain SpO2 of 88% to 92%, according to Bottrell.

Full Story

slide_6

Inhaler Device Chart

 

inhaler device chart

COPD patients who received a combination of long-acting beta agonists and inhaled corticosteroids were less likely to die or require hospitalization because of their breathing disorder, compared to people receiving only one of the two medications, Canadian researchers report.

The study findings were published in the Sept. 17 issue of the Journal of the American Medical Association.

The findings go against the official guidelines for treating COPD, but actually support what most chest physicians are doing in the clinic, said lead author Dr. Andrea Gershon, a scientist with the Sunnybrook Health Sciences Center and the Institute for Clinical Evaluative Sciences in Toronto.

Read article below pdf format:

copdlung

Combo Therapy Best for COPD: Study – WebMD

Chest Article:

The report, presented by researchers at the Centers for Disease Control and Prevention (CDC), finds:

  • In 2010, the total national medical costs attributable to COPD were estimated at $32.1 billion dollars annually.
  • Absenteeism costs were $3.9 billion for a total burden of $36 billion in COPD-attributable costs.
  • An estimated 16.4 million days of work were lost due to COPD each year.
  • Of the medical cost, 18% was paid for by private insurance, 51% by Medicare, and 25% by Medicaid.
  • The study also projects a rise in medical costs from $32.1 billion in 2010 to $49 billion by 2020.

Results:  In 2010, total national medical costs attributable to COPD and its sequelae were estimated at $32.1 billion and total absenteeism costs were $3.9 billion for a total burden of COPD-attributable costs of $36 billion. An estimated 16.4 million days of work were lost because of COPD. Of the medical costs, 18% was paid for by private insurance, 51% by Medicare, and 25% by Medicaid. National medical costs are projected to increase from $32.1 billion in 2010 to $49.0 billion in 2020. Total state-specific costs in 2010 ranged from $49.1 million in Wyoming to $2.8 billion in California: medical costs ranged from $42.5 million in Alaska to $2.5 billion in Florida and absenteeism costs ranged from $8.4 million in Wyoming to $434.0 million in California.

Conclusion:  Costs attributable to COPD and its sequelae are substantial and are projected to increase through 2020. Evidence-based interventions that prevent tobacco use and reduce clinical complications of COPD may result in potential decreased COPD-attributable costs.

COPD-in-the-us-large

COPD COSTS

Tudorza Pressair, distributed by Forest Laboratories subsidiary Forest Pharmaceuticals of St. Louis, is a long-acting dry powder that is inhaled twice a day to help the muscles of the large airways stay relaxed and open to improve airflow.

COPD Drug Tudorza Pressair Wins FDA Approval – Medical News Today

 

Tudorza- How to Use

tudorza-pressair-inhaler

What is COPD and Empysema

what is cold

Living Well with COPD

Content Protected Using Blog Protector By: PcDrome.
Increase your website traffic with Attracta.com